surgery) is mandatory. Prognosis is generally excellent. Recurrence is a rare event (6%), but it can occur in the form of invasive disease.

**2022-RA-195-ESGO**  
**MIRNA-125B EXPRESSION IN EPITHELIAL OVARIAN CANCER**  
1Shashank Shekhar, 2Praveen Sharma, 3Kiran Kharsodiya, 3Pratibha Singh, 3Manu Goyal, 3Charu Sharma, 3Dharamveer Yadav. 1Obstetrics and Gynecology, All India Institute of Medical Sciences, Jodhpur, India; 2Biochemistry, All India Institute of Medical Sciences, Jodhpur, India; 3All India Institute of Medical Sciences, Jodhpur, India

**Introduction/Background**  
Most (70%) epithelial ovarian cancers (EOCs) are diagnosed late. Non-invasive biomarkers that facilitate early disease detection are needed. The microRNAs (miRNAs) represent a new class of biomarkers whose expression is aberrant in various human cancers and miRNA-125B has been shown to be overexpressed in EOC. This study was conducted to investigate plasma miRNA 125B as a diagnostic biomarkers in EOC.

**Methodology**  
A pre-surgical venous blood sample of all patients with clinically diagnosed ovarian tumors and likely to undergo surgery was drawn. After histopathological confirmation of benign or malignant epithelial ovarian tumor of surgically resected specimen, patients were enrolled into the study and their blood sample were further analysed for miRNA-125B expression. Patients with epithelial ovarian cancer on histopathological examination were defined as cases and those with benign pathology report served as controls. Commercial kits were used to isolate RNA including miRNA from serum samples. The RNA were then be reverse-transcribed into cDNA using cDNA synthesis kit as per the manufacturer’s protocol. The Ct values of housekeeping U6 snRNA and test cDNA using cDNA synthesis kit as per the manufacturer’s protocol. The Ct values of housekeeping U6 snRNA and test cDNA using cDNA synthesis kit as per the manufacturer’s protocol. The Ct values of housekeeping U6 snRNA and test cDNA using cDNA synthesis kit as per the manufacturer’s protocol.

**Results**  
We enrolled 20 cases of Epithelial ovarian cancer and 20 cases of benign epithelial ovarian tumor. Real time relative quantification analysis showed more than 12 fold increase in serum miR-125B expression among epithelial ovarian cancer patients than the corresponding benign counterparts.

**Conclusion**  
Circulating miRNA-125B has the potential to become a novel biomarker for early diagnosis and prognosis prediction of epithelial ovarian cancer.

**2022-RA-209-ESGO**  
**A RETROSPECTIVE STUDY OF OVARIAN CANCER AMONG ELDERLY – EVALUATION AND PROGNOSIS**

1,2Miriam Rivka Brezis, 3,2Shira Peleg Hasson, 3,2Elyah Shachar, 2Dan Grisaro, 4,2Ido Laskov, 3,2Tamar Safra. 1Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 4Gynecologic Oncology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

**Introduction/Background**  
Half of epithelial ovarian cancer (EOC) are diagnosed above age 65. Women over 70 have higher morbidity and mortality. Our real-life retrospective study evaluates elderly with EOC.

**Methodology**  
Women above 70 were classified as ‘elderly’ (N=233) (71-93), and bellow 70 – ‘control cohort’ (N=755) (24-70). Treatment schedule used (6-8 cycles) were 3-weekly regimen (PC-3W) – carboplatin AUC-6 + Paclitaxel 175 mg/m² on day 1 of a 21-day cycle, and weekly regimen (PC-1W) – carboplatin AUC-2 + paclitaxel 80 mg/m² on days 1, 8, and 15 of a 28-day cycle.

**Results**  
When comparing elderly to control median overall survival (mOS) was 41.26 (33.05 to 63.87) vs. 69.78 (50.07 to 75.01) months respectively (p<0.0001). No statistical differences were shown when comparing toxicities except for grade 2 anemia – 36.49% vs. 19.67% respectively (p<0.0001) and grade 2 alopecia – 44.81% vs. 60.52% respectively (p<0.0001). The use of PC-1W vs. PC-3W was 44.29% vs 47.14% in the elderly compared to 39.03% vs. 60.3% in the control (p<0.0001).

**Conclusion**  
In our centre, Suidan et al’s RS1 and RS2 models were able to predict cyto-reductive outcomes. Predictive models may help determine patient suitability for curative surgery in AOC.

**2022-RA-198-ESGO**  
**A VALIDATION STUDY OF TWO PRE-OPERATIVE PREDICTIVE MODELS IN THE TREATMENT PLANNING OF ADVANCED OVARIAN CANCER**

Amy MacDonald Shearer, Saurabh Phadnis, James Dilley, Barts Health NHS Trust, London, UK

**Introduction/Background**  
In advanced ovarian cancer (AOC) optimal cytoreductive surgery, <1 cm visible disease (VD), is associated with improved survival. Survival rates in patients with a suboptimal cytoreduction are equivocal. Surgery can be extensive and associated with significant morbidity and mortality. Tumour resectability and patient co-morbidity affect treatment planning. Pre-operative predictive models may provide an objective measure to aid this decision-making process. This study aimed to externally validate the ability of two pre-operative predictive models (Sudan et al 2014, 2017) to determine the likelihood of suboptimal cytoreductive surgery (>1 cm VD) and any residual disease in the treatment of AOC in a London teaching hospital.

**Methodology**  
Between January 2018- June 2020, 236 patients were treated for AOC in a London Teaching Hospital. 145 had cytoreductive surgery. 6 had incomplete records and were excluded. Suidan et al (2014, 2017) model’s resectability score 1 (RS1) (suboptimal cytoreduction) and resectability score 2 (RS2) (any residual disease) were used to score patients against clinical and radiological criteria. Receiver operating characteristic (ROC) curve analysis was used to determine the accuracy of models.

**Results**  
The optimal cytoreductive surgery rate was 88.28% (n=128), 80.69% (n=117) had no visible disease, Both RS1 and RS2 models predicted surgical outcomes. RS1 AUC 0.862 (95% CI: 0.8189 to 0.9067, P<0.0001), RS2 AUC 0.869 (95% CI 0.8263 to 0.9126, P<0.0001).

**Conclusion**  
In our centre, Suidan et al’s RS1 and RS2 models were able to predict cyto-reductive outcomes. Predictive models may help determine patient suitability for curative surgery in AOC treatment.
was 57.17 vs. 30.00 months for PC-1W and PC-3W respectively (p = 0.0075). No differences in toxicity were shown, when comparing PC-1W to PC-3W in elderly except for grade 2 alopecia – 26.21% vs. 65.18% respectively (p<0.0001), and grade 2 neuropathy – 20.19% vs. 36.61% respectively (p=0.0119).

Conclusion mOS is reduced in elderly, though better than expected, furthermore toxicity is tolerable in elderly. PC-1W was both more abundant and had better mOS in the elderly population. Therefore PC-1W regimen may offer advantages for elderly in terms of tolerance while retaining efficacy.